Pharvaris
Dr. Souverijns joined the company in 2021 with over 25 years of experience in pharmaceutical portfolio strategic and operational leadership at ObsEva, Celgene, and Amgen.
Dr. Souverijns joined Pharvaris from his most recent position as the Chief Commercial Officer at ObsEva where he was responsible for the commercialization of its women’s health product portfolio. Prior to joining ObsEva, he spent 11 years at Celgene where he contributed to the successful build out of the product portfolio in diverse strategic and operational leadership roles. He developed a broad pharmaceutical background through various international assignments at PwC Consulting and in different market access roles at Amgen, both at the European and global level. Dr. Souverijns holds a degree in bio-engineering from the KU Leuven, Belgium, and obtained a Ph.D. from the same institute.
This person is not in any teams
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.